AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01081158
Drug: Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.~Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days.
Trial: NCT01081158
Drug: Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.~Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days.
Trial: NCT00067561
Drug: Alosetron
RxNorm normalized name: Alosetron
DrugBank: Alosetron (DB00969)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02685397
Drug: Leuprolide Acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
Trial: NCT02685397
Drug: Goserelin Acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
Trial: NCT02685397
Drug: Triptorelin
RxNorm normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
Trial: NCT02685397
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
Trial: NCT04188951
Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
RxNorm normalized name: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive 17 cycles of pembrolizumab via IV infusion of 200 mg over a period of 30 minutes, every 3 weeks starting no later than 90 days from the date of salvage head and neck therapy.
Trial: NCT01911351
Drug: Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to the intervention arm will receive nitrous oxide plus standard management for their minor procedure.
Trial: NCT00287781
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00943761
Drug: Vaniprevir 600 mg b.i.d.
DrugBank: Vaniprevir (DB11929)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
Trial: NCT00943761
Drug: Vaniprevir 300 mg b.i.d.
DrugBank: Vaniprevir (DB11929)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
Trial: NCT00943761
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
Trial: NCT00943761
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (\<75 kg or ≥75 kg, respectively), for 48 weeks
Trial: NCT01708044
Drug: Pramlintide acetate
RxNorm normalized name: Pramlintide Acetate
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04841993
Drug: Cannabis decoction
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 100 mL dose of cannabis decoction is administered containing 1.8 mg THC and 2.7 mg CBD.
Trial: NCT04841993
Drug: Vaporized cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg of vaporized cannabis is administered by Volcano vaporizer, wich containing 0.6-2 mg THC and 0.8-3 mg CBD
Trial: NCT00444106
Drug: Artesunate-mefloquine
RxNorm normalized name: artesunate and mefloquine
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00444106
Drug: Atovaquone-proguanil
RxNorm normalized name: atovaquone-proguanil
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02004301
Drug: Radiolabelled T4 Tablet
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02004301
Drug: Radiolabelled T6 Tablet
RxNorm normalized name: Radiolabelled DUNP19
DrugBank: RAD 502 (DB17328)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01166035
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide will be supplied as 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for oral administration.~Prior to Cycle 1, there will be a 21 day lead in treatment period with lenalidomide monotherapy (Days -21 to -1). Combination treatment will start at Day 1. Subjects will be enrolled in cohorts of three to receive a single, oral dose of lenalidomide administered on Days 1-28. For each cohort of subjects, the decision of whether or not to dose-escalate will be made after subjects have received the first treatment cycle of study drug. Treatment will continue until the occurrence of any of the following events.~* Disease progression~* Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~* Major violation of the study protocol.~* Withdrawal of consent~* Lost to follow up~* Death~* Suspected pregnancy
Trial: NCT01166035
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination treatment will start at Day 1. Subjects meeting will be enrolled in cohorts of three to receive infusions of cetuximab (400 mg/m2 first infusion only, then 250 mg/m2 subsequently) administered on Days 1, 8, 15, and 22 of each 28-day cycle. Cetuximab will be supplied as Erbitux® 22 mg/ml Vial à 50 ml, Erbitux 5 mg/ml Vial à 10 ml and Erbitux 5 mg/ml Vial à 50 ml for intravenous administration.~Treatment will continue until the occurrence of any of the following events.~* Disease progression~* Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~* Major violation of the study protocol.~* Withdrawal of consent~* Lost to follow up~* Death~* Suspected pregnancy
Trial: NCT01900665
Drug: Solanezumab
RxNorm normalized name: Solanezumab
DrugBank: Solanezumab (DB11756)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Intravenously (IV)
Trial: NCT02366325
Drug: EPO-018B
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00076440
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001937
Drug: FK463
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001937
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01039389
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
Trial: NCT01079312
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.
Trial: NCT02224534
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
Trial: NCT02224534
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.
Trial: NCT01127620
Drug: Bilastine
RxNorm normalized name: bilastine
DrugBank: Bilastine (DB11591)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 20 mg encapsulated tablets
Trial: NCT01127620
Drug: Cetirizine
RxNorm normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg encapsulated tablets
Trial: NCT00882024
Drug: Tranilast
RxNorm normalized name: Tranilast
DrugBank: Tranilast (DB07615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg tranilast tablets, bid, 12 weeks
Trial: NCT00882024
Drug: Tranilast
RxNorm normalized name: Tranilast
DrugBank: Tranilast (DB07615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg tablets, bid, 12 weeks
Trial: NCT03261921
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone is used peri -operatively mainly to prevent nausea and vomiting. Also epidural administration of dexamethasone prolong the postoperative analgesia and reduce analgesic needs
Trial: NCT03261921
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine is an alpha 2 agonist which has sedative ,analgesic, opioid sparing effect and was proved to prolong the duration of postoperative analgesia when added to local anesthetics
Trial: NCT03261921
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local anesthetic agent
Trial: NCT03402100
Drug: eye drops
RxNorm normalized name: Eye Drops
DrugBank: Tetryzoline (DB06764)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: children who received daily eye drops for myopia
Trial: NCT01310010
Drug: dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
Trial: NCT03655847
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine was injected intravenously 30 minutes before the end of operation. Single bolus is for more than 1 minute. In the first case, the dosage of dexmedetomidine was 0.1 ug/kg. If the cardiovascular reaction was positive (mean arterial pressure or heart rate was more than 20% before intravenous injection), the dosage of Dexmedetomidine in the next patient decreased by a gradient (0.05ug/kg). If the cardiovascular response was negative, the next patient increased the dose of dexmedetomidine by a gradient (0.1ug/kg); if a patient withdrew from the study, the next patient received the same dose as the patient who withdrew.
Trial: NCT02590289
Drug: BBI-5000
RxNorm normalized name: BBIBP-CorV
DrugBank: BBIBP-CorV (DB15807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBI-5000 low dose, middle dose, or high doses
Trial: NCT00005935
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005935
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00953706
Drug: Ivacaftor
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet
Trial: NCT03351348
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
Trial: NCT00665353
Drug: pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
Trial: NCT00665353
Drug: peginterferon
RxNorm normalized name: PEGINTERFERON
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
Trial: NCT00665353
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
Trial: NCT02015780
Drug: Fasiglifam
RxNorm normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasiglifam tablets
Trial: NCT03678532
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04052269
Drug: Sildenafil 100mg
RxNorm normalized name: sildenafil 100 MG
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.
Trial: NCT01734330
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00660582
Drug: Cetuximab (Erbitux)
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 500 mg/m² every second week, intravenous infusion, 8 cycles
Trial: NCT01594242
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01101529
Drug: Aprepitant (Emend)
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant will be added to the standard anti-emetic therapy. Emend is given orally, 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after
Trial: NCT02175186
Drug: ALBIS
RxNorm normalized name: Melilotus albus pollen
DrugBank: Melilotus albus pollen (DB10858)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02224170
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation, and lidocaine was infused at the rate of lidocaine 2mg Kg-1 h-1 (0.2 ml Kg-1 h-1, equivalent volume as normal saline in dexamethasone group) until the end of surgery (at the time of skin closure).
Trial: NCT02224170
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 8mg in normal saline (total volume 25mL) was infused after tracheal intubation, and normal saline was continuously infused at the rate of 0.2 ml Kg-1 h-1 until the end of surgery (at the time of skin closure).
Trial: NCT03672630
Drug: Ethambutol
RxNorm normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethambutol 25 mg/kg \[MYAMBUTOL\]
Trial: NCT03672630
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 MG \[RIFADIN\]
Trial: NCT02122380
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100 mg by mouth daily for 30 Days
Trial: NCT01783444
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane, tablets for oral use, 25 mg per day in (locally supplied)
Trial: NCT01783444
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
Trial: NCT00937495
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg given PO
Trial: NCT00937495
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.3 mg/m\^2 given IV
Trial: NCT01964183
Drug: tolterodine
RxNorm normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01964183
Drug: mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04118829
Drug: Perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For group 1 the PER dose will be administered 2-14 hours prior to sample collection. They will be administered a single dose of PER (8 mg, 12 mg or 16 mg) followed by 4 mg/day for 14 days starting on postoperative day 1 (if continued prophylaxis with PER is needed).~It is anticipated that patients in group 2 will have the daily dose of PER in these individuals will range from 4 - 12 mg/day.
Trial: NCT01581684
Drug: BI 411034
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose solution for oral administration
Trial: NCT01581684
Drug: BI 411034
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose solution for oral administration
Trial: NCT01581684
Drug: BI 411034
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose solution for oral administration
Trial: NCT00003614
Drug: estramustine phosphate sodium
RxNorm normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003614
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01042314
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 5 mg, Once Daily, Days 1-28
Trial: NCT01042314
Drug: BMS-708163
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule, Oral, 125 mg, Once Daily, Days 15-28
Trial: NCT01628913
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 10 mg qd p.o. (by mouth, daily)
Trial: NCT04592341
Drug: Gantenerumab
RxNorm normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gantenerumab will be administered by SC injection at a dose of 120 mg Q4W for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg Q2W for another 12 weeks, followed by the target dose 255 mg Q1W for up to Week 103 and an optional dose of 255 mg Q1W for up to Week 207.
Trial: NCT01652781
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
Trial: NCT00090376
Drug: GPI 1485
RxNorm normalized name: GPI-1485
DrugBank: GPI-1485 (DB05814)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00560508
Drug: Pramipexole Immediate Release
RxNorm normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: titrated as individually needed (0.25 mg - 4.5 mg daily)
Trial: NCT00560508
Drug: Pramipexole Extended Release
RxNorm normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: titration as individually needed (0.375 mg -4.5 mg daily)
Trial: NCT01248793
Drug: Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab 50 mg SC injection every 4 weeks for 48 weeks
Trial: NCT01248793
Drug: Golimumab (placebo group)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48